Cormorant Asset Management, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001583977

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2026 · 57 positions · Total reported value $1.40B · Top-10 concentration 56.4% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 81.4% · 9 new · 37 cut · 2 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -24.1% · vs SPY -26.2% · Prev Value $1.95B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -13.0% · vs SPY -15.1% · Latest Value $1.40B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Cormorant Asset Management, LP disclosed 57 equity positions with a combined reported value of $1.40B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 56.4% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were PBLS ($149.04M), PRAX ($145.62M), RAPP ($82.57M). By sector, the heaviest allocations are Health Care 92.7%, Industrials 1.3%. Versus the prior quarter, allocation shifted toward Other (+4.3pp) and away from Health Care (-0.7pp), Industrials (-3.8pp).

Versus the prior quarter, Cormorant Asset Management, LP opened 9 new positions, trimmed 37 and fully exited 2, a turnover rate of 81.4% of positions. The portfolio's overlap with the prior quarter was 81% of names.

The largest new positions opened in Q3 2026 were GRTX ($37.86M), ATOS ($30.66M), ARTV ($30.32M).

Of the 2 positions fully exited versus the prior quarter, the largest were CRNX ($4.68M), ALT ($3.80M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • GRTX ELECTRA THERAPEUTICS INC · $37.86M
  • ATOS ATOSSA THERAPEUTICS INC · $30.66M
  • ARTV ARTIVA BIOTHERAPEUTICS INC · $30.32M
  • IRD OPUS GENETICS INC · $26.62M
  • VNDA VANDA PHARMACEUTICALS INC · $19.20M
  • CUE CUE BIOPHARMA INC · $16.18M
  • ACRS ACLARIS THERAPEUTICS INC · $9.21M
  • INBX INHIBRX BIOSCIENCES INC · $5.00M

Fully Exited (vs previous quarter)

  • CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $4.68M
  • ALT ALTIMMUNE INC · prev qtr: $3.80M

Insider Transactions (Form 4)

Latest Cormorant Asset Management, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-10-29 Sell Corbus Pharmaceuticals Holdings, Inc. 425,000 $4.10 SEC filing
2026-08-10 Buy BlossomHill Therapeutics, Inc. 312,500 $16.00 SEC filing
2026-08-10 Conversion BlossomHill Therapeutics, Inc. 1,701,541 — SEC filing
2026-08-10 Conversion BlossomHill Therapeutics, Inc. 1,599,993 — SEC filing
2026-04-28 Sell BRIGHT MINDS BIOSCIENCES INC. 109,331 $89.50 SEC filing

All insider transactions →

Fund Profile

Cormorant Asset Management, LP, based in Boston, MA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 57 positions worth $1.40B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-79513 (status: Approved), registered 2014-04-15
  • Regulatory AUM (Form ADV): $3.84B as of 2026-05-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 7 private funds, of which 1 hedge funds

Portfolio Structure

  • 57 positions · $1.40B reported value (Q3 2026)
  • Top 10 holdings = 56.4% of reported value
  • Largest position: PBLS (PARABILIS MEDICINES INC) at 10.7%
  • Average position size: $24.53M

Sector Tilt

  • Health Care 92.7%
  • Industrials 1.3%
  • Financials 1.1%
  • (classified holdings cover 95% of value)

Quarterly Activity

  • Q3 2026: 9 new, 1 added, 37 reduced, 2 exited
  • 10 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund is reducing exposure across most top-10 holdings (8/10), with only 2 held steady, suggesting a cautious stance on biotech/healthcare names despite sector concentration. Weight increases for PBLS and ANL are purely price-driven, not new buys. 2. Key moves: - Reduced: PRAX (-21.9% shares), EWTX (-25.9%), DNTH (-33.3%), ABVX (-37.0%), DRUG (-11.1%), ERAS (-16.7%), RAPP (-7.5%). - Added: None in top-10 (only 9 new positions total, not disclosed). - Held: PBLS, BBOT, ANL (no share changes). 3. Portfolio structure: Highly active, concentrated in Health Care (100% top-10), with high risk appetite (small-cap biotech/therapeutics). No passive ETFs apparent. 4. Per-holding one-liner: - PBLS: Parabilis Medicines (biopharma, unverified). - PRAX: Praxis Precision Medicines (cancer therapeutics). - RAPP: Rapport Therapeutics (neuroscience, unverified). - EWTX: Edgewise Therapeutics (rare diseases, unverified). - BBOT: BridgeBio Oncology (cancer, unverified). - ERAS: Erasca (oncology, unverified). - ANL: Adlai Nortye Group (biopharma, unverified). - DNTH: Dianthus Therapeutics (kidney disease, unverified). - ABVX: Abivax (immunology, unverified). - DRUG: Bright Minds Biosciences (CNS disorders, unverified). 5. Style summary: Trimming biotech positions amid caution, retaining select names with price-driven weight hikes.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 10:34

Sector Allocation

Health Care 92.7%
Financials 1.1%
Other 4.9%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 4.62M $149.04M 10.66%
10.66%
Hold
2 500.00K $145.62M 10.42%
10.42%
Reduce
3 2.46M $82.57M 5.91%
5.91%
Reduce
4 1.86M $75.52M 5.40%
5.40%
Reduce
5 17.88M $73.30M 5.24%
5.24%
Hold
6 5.00M $73.30M 5.24%
5.24%
Reduce
7 3.98M $63.65M 4.55%
4.55%
Hold
8 500.00K $44.02M 3.15%
3.15%
Reduce
9 425.00K $42.08M 3.01%
3.01%
Reduce
10 800.00K $39.86M 2.85%
2.85%
Reduce
11 3.37M $37.86M 2.71%
2.71%
New
12 2.86M $33.41M 2.39%
2.39%
Reduce
13 400.00K $33.32M 2.38%
2.38%
Reduce
14 1.79M $30.66M 2.19%
2.19%
New
15 1.03M $30.58M 2.19%
2.19%
Hold
16 1.82M $30.32M 2.17%
2.17%
New
17 2.47M $27.37M 1.96%
1.96%
Hold
18 5.50M $26.62M 1.90%
1.90%
New
19 2.11M $24.16M 1.73%
1.73%
Hold
20 375.00K $21.98M 1.57%
1.57%
Reduce
21 1.51M $20.16M 1.44%
1.44%
Reduce
22 962.90K $19.20M 1.37%
1.37%
New
23 5.75M $18.80M 1.34%
1.34%
Reduce
24 700.00K $17.46M 1.25%
1.25%
Reduce
25 800.00K $17.02M 1.22%
1.22%
Reduce
26 250.00K $16.45M 1.18%
1.18%
Reduce
27 625.28K $16.18M 1.16%
1.16%
New
28 2.34M $15.99M 1.14%
Form 4 · 1 →
1.14%
Hold
29 2.24M $15.89M 1.14%
1.14%
Reduce
30 2.08M $15.33M 1.10%
1.10%
Reduce
31 1.75M $15.12M 1.08%
1.08%
Reduce
32 450.00K $14.27M 1.02%
1.02%
Reduce
33 1.30M $13.78M 0.99%
0.99%
Hold
34 125.00K $11.13M 0.80%
0.80%
Reduce
35 275.00K $10.47M 0.75%
0.75%
Reduce
36 1.75M $9.21M 0.66%
0.66%
New
37 300.00K $8.73M 0.62%
0.62%
Add
38 4.50M $8.64M 0.62%
0.62%
Reduce
39 50.00K $5.00M 0.36%
0.36%
New
40 400.00K $4.57M 0.33%
0.33%
Reduce
41 300.00K $4.21M 0.30%
0.30%
New
42 3.57M $4.21M 0.30%
0.30%
Hold
43 50.00K $3.93M 0.28%
0.28%
Reduce
44 100.00K $3.66M 0.26%
0.26%
Reduce
45 75.00K $3.44M 0.25%
0.25%
Reduce
46 15.00K $3.42M 0.24%
0.24%
Reduce
47 125.00K $2.78M 0.20%
0.20%
Reduce
48 100.00K $2.43M 0.17%
0.17%
Reduce
49 940.00K $2.36M 0.17%
0.17%
Reduce
50 20.00K $2.28M 0.16%
0.16%
Reduce

FAQ

What did Cormorant Asset Management, LP buy in 2026-Q3?

In its 2026-Q3 13F filing, Cormorant Asset Management, LP reported 57 equity positions worth $1.40B in aggregate; its largest disclosed positions were PBLS ($149.04M), PRAX ($145.62M), RAPP ($82.57M).

How large is Cormorant Asset Management, LP's portfolio?

Cormorant Asset Management, LP reported $1.40B of long equity holdings across 57 positions as of 2026-Q3. Top-10 holdings account for 56.4% of reported value.

What is Cormorant Asset Management, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/cormorant-asset-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →